Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US market may evolve.
Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available at launch. As the author points out, oncology drugs in particular often follow the path of incremental innovation, proceeding in steps towards realising their full potential in treatment -- and even cure.
Mestre-Ferrandiz, J., Deverka, P., Pistollato, M. and Rosenberg, E.
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis. A literature review helped elucidate concepts and define focus. The authors then conducted semi-structured interviews with an international sample of 19 senior pharmaceutical executives in various positions in the five companies: R&D, outcomes research, medical affairs, and pricing and reimbursement.
Based on OHE’s 50th anniversary conference, this publication captures the views of thought leaders from around the world about the scientific and economic climate for drug development by 2022.
Four major themes stood out in the conference discussions, as reported in this publication.
1. Health care will be radically transformed as “precision” medicine plugs into the specific genetic makeup of both patients and diseases, and is paired with increasingly powerful and convenient diagnostics.
The cost of R&D for a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or for industry understanding of its performance, but because they are a key aspect of the international debate about the reasonableness of pharmaceutical prices and the magnitude of the long-term investments involved.
O’Neill, P., Puig-Peiro, R., Mestre-Ferrandiz, J. and Sussex, J.
Since 1996, in its yearly PPRS Report to Parliament, the Department of Health in England has published international price comparisons of branded medicines used in the primary care setting. OHE Consulting uses the same methodology in this report to update comparisons through 2011.
This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar. It focuses primarily on the reasons for a decline since 2000 in the average number of new drugs launched per year by the pharmaceutical industry. Factors identified as important include a trend towards targeting more complex and difficult diseases, the need to adapt to dramatic changes in scientific knowledge and in R&D approaches, and substantial changes in both the regulatory and marketing climates.
This report provides a clear explanation of the nature of innovation in medicines. A fully revised and expanded version of the 2005 edition, it updates the literature review of the economics of innovation, traces important innovation that has occurred since 2005, adds new case studies and updates the discussion of competition in pharmaceutical R&D.